Drugs / Dorgenmeltucel-L
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT00300612 | Mar 2006 → Sep 2007 | melanoma | NewLink Genetics Corporation | Completed | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT02054520 | Jun 2014 → Apr 2018 | metastatic melanoma | NewLink Genetics Corporation | Terminated | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Dorgenmeltucel-L | “A Phase I/II Study of Dorgenmeltucel-L (HyperAcute Melanoma) an Antitumor Vaccination Using Alpha(1,3)Galactosyltransferase Expressing Allogeneic Tumor Cells” NCT00300612 ↗1“Dorgenmeltucel-L is composed of irradiated allogeneic melanoma cell lines (HAM-1, HAM-2 and HAM-3).” NCT02054520 ↗ |
| Known as | HyperAcute Melanoma | “A Phase I/II Study of Dorgenmeltucel-L (HyperAcute Melanoma) an Antitumor Vaccination Using Alpha(1,3)Galactosyltransferase Expressing Allogeneic Tumor Cells” NCT00300612 ↗ |
| Modality | Vaccine | “genetically engineered HyperAcute-Melanoma vaccine” NCT00300612 ↗ |
| Route | Other | “series of twelve intradermal injections” NCT00300612 ↗ |